Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy
Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer
Oligomerix Presents Preclinical Data at TAU2020 Global Conference for Small Molecule Inhibitor of Tau Self-Association